Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635 | ISIN: INE0DK501011 | Industry: Pharmaceuticals
| Expensive Performer

211.1400 4.42 (2.14%)

NSE May 07, 2025 12:04 PM

31.43% Fall from 52W High

Volume: 2.0M

Piramal Pharma Ltd.

25 Sep 2024

211.14

2.14%

Geared to drive robust operating leverage across segments

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment.

Piramal Pharma Ltd. has gained 35.35% in the last 1 Year